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the regulation of appetite
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The gastrointestinal (GI) tract senses the ingestion of food and responds by signaling 
to the brain to promote satiation and satiety. Representing an important part of the 
gut–brain axis, enteroendocrine L-cells secrete the anorectic peptide hormones glu-
cagon-like peptide-1 (GLP-1) and peptide YY (PYY) in response to the ingestion of 
food. The release of GLP-1 has multiple effects, including the secretion of insulin from 
pancreatic β-cells, decreased gastric emptying, and increased satiation. PYY also slows 
GI motility and reduces food intake. At least part of the gut–brain response seems to 
be due to direct sensing of macronutrients by L-cells, by mechanisms including specific 
nutrient-sensing receptors. Such receptors may represent possible pathways to target to 
decrease appetite and increase energy expenditure. Designing drugs or functional foods 
to exploit the machinery of these nutrient-sensing mechanisms may offer a potential 
approach for agents to treat obesity and metabolic disease.
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introduction
The gastrointestinal (GI) tract represents the largest endocrine organ in the human body. 
Enteroendocrine cells (EECs) are located throughout the GI tract, constituting <1% of the cell 
population in the intestinal epithelium, but playing critical physiological roles and representing an 
important component of the gut–brain axis (1). At least 15 types of EEC have been described, capable 
of secreting over 20 peptide hormones that influence processes including gut motility, gastric acid 
secretion, and energy intake. It was previously thought that EECs could be separated into discrete 
classes of cells with specific secretory profiles. Examples of previously characterized cell families 
include gastrin-secreting G-cells, cholecystokinin (CCK)-secreting I-cells, glucagon-like peptide 
(GLP-1), and peptide YY (PYY)-secreting L-cells, among others (2). However, recent work has sug-
gested that EEC families may be less well defined, with EECs existing as a wide range of cell types 
that secrete various combinations of different peptides (3).
Abbreviations: AgRP, agouti-related peptide; AMPK, adenosine monophosphate-activated protein kinase; AP, area postrema; 
ARC, arcuate nucleus; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; CTA, 
conditioned taste aversion; DPPIV, dipeptidyl peptidase IV; EEC, enteroendocrine cell; FACS, fluorescence-activated cell 
sorted analysis; FFARs, free fatty-acid receptors; FoxO, forkhead box class O; GABA, γ-aminobutyric acid; GI, gastroin-
testinal; GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide 1; GLP-2, glucagon-like peptide 2; GLUT2, glucose 
transporter 2; GPCR, G-protein coupled receptors; KATP, ATP-sensitive potassium channel; LCFAs, long-chain fatty acids; 
MCFAs, medium chain fatty acids; MOR, mu-opioid receptor; mTOR, mammalian target of rapamycin; NPY, neuropeptide Y; 
NTS, nucleus of the solitary tract; OEA, oleoylethanolamide; PEPT1, peptide-transporter 1; POMC, pro-opio melanocortin; 
PYY, peptide YY; SCFAs, short-chain fatty acids; SGLT-1, sodium-glucose transporter 1; T1Rs, type 1 taste receptors; TORC1, 
TOR complex 1.
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Nervous and endocrine signaling between the gut and the 
brain allows the modulation of GI functions to increase the 
efficiency of digestion, and the communication of energy and 
nutritional requirements to the brain to influence appetite. One 
key function of EECs is to sense luminal contents, which will then 
modulate their release of hormones that regulate food intake. To 
achieve this, open-type cells often have a distinct cone-shaped 
morphology with one extremity adjacent to the basal lamina and 
the other possessing microvilli on apical processes (Figure  1). 
Microvilli are thus in immediate contact with the luminal 
contents, sensing of which can lead to the release of hormones 
from secretory granules directly into the nearby blood vessels (4). 
G-protein coupled receptors (GPCRs) represent over one-third 
of therapeutic drug targets, and a number detect dietary com-
ponents. When the products of food breakdown move through 
the GI tract, specific macronutrients stimulate the chemosensors 
of a variety of GPCRs. This leads to the modulation of gut hor-
mone release, which will influence neuronal signaling in appetite 
centers in the brain to mediate the appropriate feeding behavior, 
by, for example, the termination of hunger and the induction 
of satiety (5). In contrast, closed-type EECs do not come into 
contact with luminal nutrients, and instead react to neural or 
circulating signals, though they also play a role in the regulation 
of food intake. In addition, the hormones released from EECs can 
have paracrine effects on nearby cells, including neurones. Recent 
evidence also suggests that EECs interact directly with neurones 
via synapse-like structures named neuropods (6, 7).
The human body stores excess energy intake as adipose 
tissue. The present obesity pandemic is a major global health 
issue, which has arisen due to the abundance of highly palatable, 
calorie-dense food combined with reduced levels of physical 
activity. The pharmacological agents for weight loss currently 
available are only modestly effective. Having previously been 
advocated for use in the morbidly obese, bariatric surgery is now 
recommended for obese patients with type II diabetes in UK (8). 
However, the number of patients that now qualify suggests that 
this is an impractical approach to dealing with obesity. Targeting 
gut hormone receptors to decrease appetite and increase energy 
expenditure is a major area of interest for the management of 
body weight (9–11), and the GLP-1 receptor agonist Liraglutide 
(Saxenda) has recently been approved by the U.S. Food and Drug 
Administration as a treatment for obesity (12). However, the 
formulation of foodstuffs, which contain targeted nutraceuticals 
to exploit the various nutrient-sensing systems, present on EECs 
represents another possible approach to the treatment of obesity, 
which might avoid the problems of administration, nausea, 
and tachyphylaxis that have been associated with gut hormone 
administration (Table 1) (13–15).
FiGURe 1 | Summary of the macronutrient sensing receptors 
expressed in enteroendocrine cells of the gut and the hormones 
they release. An open-type enteroendocrine cell possesses microvilli 
extending into the gut lumen, coming into direct contact with 
macronutrients. Food components are sensed by various GPCRs and 
transporters located on the apical border. GI tract hormones are released 
into the circulation, acting via paracrine, endocrine, and neural pathways to 
modulate food intake. LCFA; long-chain fatty acid, 7TM; 7-transmembrane, 
CaSR; calcium-sensing receptor, GPRC6A; G-protein coupled receptor 
family C group 6 subtype A, GPR93; G-protein coupled receptor 93, SCFA; 
short-chain fatty acid, FFAR; free-fatty-acid receptor, OEA; 
oleoylethanolamide, GPR119; G-protein coupled receptor 119, GI; 
gastrointestinal, PYY; peptide YY, GLP; glucagon-like peptide, CCK; 
cholecystokinin, GIP; gastric inhibitory peptide.
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The Hormonal Products of L-Cells
Gastric distension and the release of upper-intestinal tract 
hormones, such as CCK from I-cells, trigger short-term satia-
tion processes in the upper GI tract (4). However, longer-term 
satiety is likely driven by other mechanisms, which may include 
the direct sensing of nutrients leading to the release of anorectic 
gut hormones from enteroendocrine L-cells. Mature L-cells are 
commonly defined as EECs that express the preproglucagon gene. 
Posttranslational processing of preproglucagon is tissue-specific, 
and hence, yields different hormonal products in the pancreas 
and intestine. L-cells, which have traditionally been described as 
having a distinct cone-shaped morphology, secrete the products 
of cleavage by prohormone convertase 1; GLP-1, glucagon-like 
peptide 2 (GLP-2), glicentin, and oxyntomodulin (34–36). 
EECs have been suggested to express an overlapping spectrum 
of hormones dependent on spatial distribution and exposure to 
nutrients (3, 37). Immunostaining and fluorescence-activated 
cell sorted analysis (FACS) have revealed that L-cells co-secrete 
distinct peptides depending on their location. L-cells in the upper 
small intestine demonstrate co-localization with gastric inhibitory 
peptide (GIP), and thus, bear some resemblance to neighboring 
K-cells, while L-cells in the lower small intestine show high levels 
of co-localization with PYY and CCK. The GLP-1 and PYY co-
expressing L-cells are typically considered to be involved in the 
regulation of energy homeostasis, in addition to other functions. 
GLP-1 mediates its effects via the GLP-1 receptor. PYY exists in 
two major circulating forms: the full-length peptide, PYY1–36, 
and a truncated form, PYY3–36. Full-length PYY acts on Y family 
receptors Y1, Y2, and Y5, whereas PYY3–36 is relatively selective 
for the Y2 receptor (38, 39).
L-cells that co-express GLP-1 and PYY are located along 
much of the length of the GI epithelium, starting at the proximal 
jejunum and increasing in density along the small intestine and 
then the large intestine. Thus, the contact of ingested nutrients 
with L-cells increases along the GI tract (34, 40). GLP-1 and 
PYY exhibit a two-phase release profile. The initial rapid rise in 
GLP-1 may partially represent release from L-cells in the upper 
small intestine. However, it is thought that most of this first phase 
response for GLP-1 and that of PYY is mediated via a neural reflex 
or a circulating factor (41, 42). The arrival of food in the distal 
TABLe 1 | A summary of potential targets for the treatment of obesity and their mechanisms.
Potential targets Mechanism Reference
Oxyntomodulin GLP-1 and glucagon receptor agonism (10, 16)
Peptide YY Y2R agonism modulates central anorectic pathways and influences ileal brake (17, 18)
Dietary supplementation with glutamine and l-arginine Ingested glutamine and l-arginine potentiate the release of GLP-1 and PYY, via 
activation of AMPK and mTOR
(19–22)
Calcium-sensing receptor Activation by specific l-amino acids stimulates the secretion of GLP-1 and PYY (23)
G-protein coupled receptor 93 Protein hydrolyzates stimulate the release of CCK (24)
G-protein coupled receptor, class C, group 6, subtype A Activation by specific l-amino acids stimulates the secretion of GLP-1 (25, 26)
Sodium-glucose transporter 1 Transport of ingested glucose into enterocytes stimulates the secretion of GLP-1 (27)
Free fatty acid receptor 2 and 3 Activation by short-chain fatty acids may stimulate the secretion of GLP-1 and PYY  
and inhibit gastrointestinal motility
(28–30)
Free fatty acid receptor 1 and 4 Activation by medium and long-chain fatty acids stimulates the secretion of GLP-1 (31–33)
gut is thought to drive the second phase of the release of GLP-1 
and PYY into the circulation, by activation of specific nutrient 
receptors and other cellular machinery present on apical cell 
processes (43, 44).
Hormonal Products of L-Cells:  
Peripheral effects
L-cell-secreted GLP-1 and PYY diffuse into the lamina propria 
and enter the systemic circulation via the hepatic portal vein. 
Systemic circulating levels of both hormones rise within 15 min 
of food ingestion in humans, with levels approximately propor-
tional to the calories ingested. Following a mixed meal, plasma 
concentrations of GLP-1 and PYY peak at around 40 and 90 min, 
respectively, then reach a plateau (45, 46). GLP-1 and PYY circu-
late at basal levels in the fasting state, with concentrations rising 
rapidly postprandially; an effect that seems to be larger in humans 
than in rodents (41, 47–50). Following release, both GLP-1 and 
PYY undergo enzymatic cleavage in the intestinal endothelium 
and liver by dipeptidyl peptidase IV (DPPIV), which converts 
GLP-1 to an inactive form, and truncates PYY1–36 to its Y2 selec-
tive form, PYY3–36.
Glucagon-Like Peptide-1
The release of GLP-1 has several peripheral consequences, the 
most notable being its incretin effect. GLP-1 and GIP are reported 
to bind their respective receptors on β-cells in the pancreas in 
response to glucose (Figure 2). This leads to an increase in the 
concentration of intra-cellular calcium, and consequent exocyto-
sis of insulin-containing vesicles (51). Glicentin has a similar but 
less potent effect, though a glicentin-specific receptor remains to 
be identified (52, 53). However, there is some controversy sur-
rounding the incretin role of GLP-1 due to the relatively small 
increase in circulating GLP-1 observed postprandially, and the 
short lifespan of the peptide (54). Specific knockdown of Glp1r 
in the pancreatic β-cells of mice impairs glucose tolerance in 
response to hyperglycaemmia, and attenuates insulin secretion 
in response to exogenous GLP-1. However, a DPPIV inhibitor 
retained its glucose lowering effects in these mice, suggesting that 
the GLP-1R on the beta cell is not necessary for these effects, and 
FiGURe 2 | A summary of the target areas of L-cell secreted PYY 
and GLP-1. Following nutrient ingestion, PYY and GLP-1 diffuse into the 
lamina propria and enter the circulation. GLP-1 binds its receptors on 
pancreatic β-cells, leading to insulin secretion (51). Full-length PYY binds 
pancreatic Y1 receptors and inhibits glucose-stimulated insulin secretion, 
while PYY3–36 may exert effects on glucose homeostasis via extra-islet Y2 
receptors (56, 57). Circulating hormones are able to access areas of the 
hindbrain with a leaky blood–brain barrier, such as the area postrema, 
which communicates with the nucleus of the solitary tract (58). GLP-1 and 
PYY3–36 may signal via the vagus to central hypothalamic nuclei controlling 
energy homeostasis, where receptors for these hormones are widely 
expressed (46, 59–61).
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that perhaps extra-islet receptors are responsible for the incretin 
effects of GLP-1. However, this may also reflect compensatory 
action by other DPPIV substrates (55).
In addition to acute effects, GLP-1 exhibits trophic effects on 
β-cells (62–65); a 2-day infusion of GLP-1 increased markers of 
proliferation, and decreased markers of apoptosis in the pancreas 
of Zucker diabetic rats (Figure  3) (66). This is thought to be 
mediated by the activation of transcription factors that result 
in enhanced proliferation and differentiation, and inhibition of 
apoptosis, thereby promoting islet growth (63, 66).
Vagal nervous activity can reduce gastric emptying, thus, 
slowing nutrient absorption. The slowing of gastric emptying 
by GLP-1 is subject to rapid tachyphylaxis following chronic 
exposure, likely at the level of the vagus nerve. In human, 
subjects given a continuous intravenous infusion of GLP-1, 
post-prandial concentrations of glucose, glucagon, and insulin 
progressively increased in subsequent meals. Therefore, it is 
possible that part of the glycemic control afforded by adminis-
tration of GLP-1 occurs secondary to delayed gastric emptying 
(14). The related peptide, GLP-2, is co-secreted with GLP-1, 
and contributes to optimizing the local environment for nutri-
ent absorption. GLP-2 induces crypt cell proliferation, while 
also preventing the apoptosis of intestinal cells and increasing 
GI blood flow (67, 68). Peripheral administration of GLP-2 
also increases the expression of cellular transport machinery 
involved in glucose absorption in the rat jejunum, such as the 
sodium-glucose transporter 1 (SGLT-1) and glucose transporter 
2 (GLUT2) (69, 70).
Originally demonstrated by an infusion of corn oil, adminis-
tration of carbohydrate, lipid, and protein directly into the ileum 
of humans also stimulates the “ileal brake,” which results in the 
secretion of PYY and GLP-1, reduced food intake, and satiation 
(71–73). The ileal break is a feedback mechanism initiated by the 
presence of unabsorbed dietary components in the ileum, and 
acts to slow more proximal GI motility in order to allow efficient 
digestion and uptake of nutrients. GLP-1 and PYY appear to be 
important components of this system (Figure  2). Exogenous 
administration of PYY3–36 or GLP-1 decreases gastric emptying 
FiGURe 3 | A summary of the effects of GLP-1, PYY3–36, and the combined effects of both.
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and pancreatic secretion (14, 18, 74) and decreases the speed 
of intestinal transit, an effect, which may partly be due to the 
inhibited release of motilin by PYY, and a consequent decrease 
in intestinal migrating contractions (17, 75). However, activation 
of Y1 receptors by PYY1–36 tonically accelerates colonic transit, an 
effect, which is attenuated by antagonism of this receptor (76), 
and which is perhaps designed to empty the colon to allow it to 
deal with the nutrients coming down the small intestine. Binding 
of PYY1–36 to the Y1 inhibitory receptor subtype in the gastric 
mucosa also regulates the function of gastric endocrine cells, 
inhibiting vagally stimulated gastric acid secretion (77).
Peptide YY
In addition to appetite regulation, PYY may regulate pancreatic 
islet function to regulate glucose homeostasis. Full-length PYY1–36 
inhibits glucose-stimulated insulin secretion from murine islets, 
an effect thought to be mediated via neuropeptide Y (NPY) Y1 
receptors. In accord with this, Pyy-null mice, or islets in which the 
Y1 receptor is absent, hypersecrete insulin (56, 57). The absence 
of the Y2 receptor in human and murine pancreatic islets corre-
sponds to the lack of a direct effect of PYY3–36 on glucose-stimulated 
insulin secretion (78). However, the peripheral administration of 
exogenous PYY3–36 or Y2R agonist, administered either in the fed 
state or in combination with glucose, improved glucose toler-
ance, and stimulated insulin secretion in mice. This effect was 
abolished by the administration of a peripheral Y2R antagonist, 
implying that PYY3–36 exerts its effects on glucose homeostasis 
via extra-islet Y2 receptors in a nutrient-dependent manner (57). 
Endogenous PYY3–36 may act via the Y2R to increase hepato-
portal GLP-1, as the effect was attenuated by administration of 
the GLP-1R antagonist, Exendin9-39 (57). However, a combined 
intravenous infusion of PYY3–36 and GLP-1 to overweight subjects 
increased first phase insulin secretion to the same level as GLP-1 
alone; thus, the addition of PYY3–36 had no additive effects at the 
doses tested in an acute setting (79).
Oxyntomodulin
Oxyntomodulin, a longer isoform of glucagon, is a dual agonist of 
the GLP-1 and glucagon receptors, though with a 10- to 100-fold 
lower affinity than the native ligands (16, 80, 81). Unsurprisingly, 
the effects of oxyntomodulin combine those of GLP-1 and 
glucagon. Centrally injected oxyntomodulin reduces food intake 
to the same magnitude as GLP-1, despite a much lower receptor 
affinity (16). Exogenous administration reduces food intake in 
rodents and humans, an effect mediated by the GLP-1 receptor, 
and also modulates gastric acid and exocrine pancreatic secretion 
(82–84). Chronic pre-prandial administration of oxyntomodulin 
drove significant weight loss in overweight and obese human 
subjects (10). Studies in pair-fed rats suggested that, in addi-
tion to decreased energy intake, oxyntomodulin-stimulated 
weight loss may be the result of increased energy expenditure 
(84). Subsequent human data confirmed that oxyntomodulin 
increased activity-related energy expenditure, though not resting 
energy expenditure, following pre-prandial subcutaneous self-
administration in overweight subjects (10). The beneficial actions 
of oxyntomodulin on food intake, energy expenditure, and body 
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weight place it at the forefront of peptides of interest in the treat-
ment of obesity. Modifying the N-terminus of oxyntomodulin, 
which confers resistance to enzymatic degradation by DPPIV, 
has shown significant therapeutic potential in terms of improved 
glycemic control and appetite suppression (85, 86).
Hormonal Products of L-Cells:  
The Gut–Brain Axis
A number of brain regions are involved in the central regulation 
of energy homeostasis, including the hypothalamus, the cortex, 
the limbic system, and the brain stem (87). The hypothalamus 
is divided into distinct nuclei that co-ordinate orexigenic and 
anorexigenic signals. The arcuate nucleus (ARC) is located 
proximate to the median eminence, an area with an incomplete 
blood–brain barrier, and is therefore in contact with circulating 
factors, including PYY and GLP-1. Within the ARC two distinct 
sets of neurons have opposing effects on appetite. Activation 
of pro-opio melanocortin (POMC) neurons inhibits appetite, 
while activation of NPY/agouti-related peptide (AgRP) neurons 
stimulates appetite (88–91). These neuronal populations project 
to intra- and extra-hypothalamic regions to regulate energy 
homeostasis. The nucleus of the solitary tract (NTS) in the brain-
stem receives input from the periphery via vagal afferent fibers, 
transmitting information, such as gastric distension, ingested 
dietary composition, and water content. Vagal efferent fibers are 
located in the dorsal motor nucleus, which is located ventral to 
the NTS in the caudal brainstem (92). These brain regions are 
critical to the control of energy homeostasis, and are thus the 
target regions for central pharmacological manipulation, with 
the hope that drugs acting specifically in these areas will display 
fewer unwanted side-affects.
GLP-1 in the Gut–Brain Axis
The rapid breakdown of GLP-1 results in a half-life of approxi-
mately 2 min. Concentrations of GLP-1 are therefore highest in 
the intestinal submucosa, decreasing in the hepatic portal vein and 
systemic circulation. An estimated 15% of active GLP-1 secreted 
from the porcine intestine reaches the systemic circulation, 
before it is also degraded by DPPIV (93). Consequently, there is 
debate as to whether physiologically relevant levels in men are 
able to reach central GLP-1 receptors in the hypothalamus and 
brainstem, where centrally produced GLP-1 is also thought to act 
as a neuropeptide (94, 95). It has been suggested that peripheral 
GLP-1 may act via a neural rather than an endocrine route, 
activating receptors near its site of release before the peptide 
encounters endothelial DPPIV. Receptors for GLP-1 are located 
on enteric neurons that exhibit increased action potential firing in 
primary culture following the application of GLP-1, which may, 
for example, inhibit local muscle tone as part of the ileal brake 
(96). Receptors on sensory afferent fibers of the nodose ganglion 
may also be activated, relaying impulses to central regions 
important in energy homeostasis, such as the NTS and the hypo-
thalamus (93). Expression of the GLP-1 receptor in neuronal cells 
of the ganglion has been confirmed by Nakagawa et al., who also 
demonstrated that intraportal injection of physiological levels 
of GLP-1 increased afferent signaling of the rat hepatic vagus, 
providing evidence for vagal chemoreception of peripheral GLP-1 
(96, 97). Interestingly, rats that had undergone subdiaphragmatic 
vagal deafferation were less sensitive to the anorectic effects of 
intraperitoneally administered GLP-1, whereas the effects of 
GLP-1 administered into the vena cava and hepatic portal vein 
were not affected over a wide range of doses. This suggests that 
while intraperitoneal GLP-1 requires abdominal vagal afferent 
signaling to exert its anorectic effects, circulating GLP-1 medi-
ates these effects via an alternative mechanism (Figure 3) (98). 
It has been suggested that exogenous intraperitoneal GLP-1 acts 
in a similar way to endogenous L-cell-secreted GLP-1, acting in 
a paracrine fashion, before DPPIV denatures the peptide within 
the capillary walls (96, 98).
As the satiating effects of intravenous GLP-1 are unaf-
fected by vagotomy, it is possible that GLP-1 administered in 
this way is acting directly at central GLP-1 receptors (98, 99). 
Circulating GLP-1 is able to diffuse across the fenestrated 
capillaries of the circumventricular organs, binding receptors 
in the subfornical organ and area postrema (AP) (58). The AP 
is positioned in close proximity to the NTS, to which it com-
municates nutritional information. The AP also has efferent 
and afferent connections to the hypothalamus, allowing it to 
moderate feeding in response to the nutritional demands (58, 
100). The GLP-1 receptor is widely expressed throughout the 
hypothalamus, with the highest expression in the PVN and 
ARC (60, 61). This coincides with dense connections from the 
NTS, which also expresses preproglucagon, highlighting the 
importance of the brainstem–hypothalamic pathway in GLP-1 
signaling (60). The PVN is thought to be the primary mediator of 
brain-derived GLP-1-induced satiation, as direct injection into 
this nuclei elicits a robust anorectic response (101, 102). GLP-1 
may also elicit its effects on food intake via the ARC, with some 
POMC neurons expressing the GLP-1 receptor (102). Indeed, 
evidence suggests that peripheral administration of liraglutide, 
a long-acting GLP-1 analog, acts on ARC POMC neurons to 
drive weight loss (61). The central expression of preproglucagon 
is highly conserved between rodents and non-human primates. 
Mapping of the GLP-1 receptor in the non-human primate brain 
is consistent with the functional role of GLP-1, with the most 
abundant expression in areas controlling energy homeostasis, 
specifically the hypothalamic and brainstem regions mentioned 
above. Interestingly, a higher level of expression of the GLP-1 
receptor was present in the amygdala of the primate brain 
compared with the rodent brain, indicating a possible species 
difference in GLP-1 signaling in this region (103).
PYY in the Gut–Brain Axis
Peptide YY has a half-life of approximately 10 min in humans, 
though plasma levels remain increased for up to 6 h postprandially 
due to sustained release (46, 104). The Y5 receptor is expressed 
throughout the brain, though most densely in the hypothalamus, 
where it is co-localized with the Y1 receptor. The Y5 receptor 
mediates the effects of NPY-induced food intake, with selective 
agonism of this receptor, resulting in stimulation of feeding 
(105). However, full-length PYY1–36 does not appear to influence 
appetite when administered peripherally, suggesting it is unable 
to access these orexigenic receptors (106).
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The most notable role of PYY3–36 is as an anorectic peptide. 
Acute peripheral administration of PYY3–36 to rodents or humans 
reduces food intake (46, 107). Intermittent exogenous adminis-
tration of PYY3–36 reduces food intake, body weight, and adiposity 
in rats, and prevents weight gain in diet-induced obese rats (108, 
109). However, the primary mechanism by which PYY3–36 reduces 
food intake is unclear. It appears to be mediated by Y2 recep-
tors; the anorectic effect of PYY is absent in mice with targeted 
gene deletion of the Y2R (46, 107). Initial studies found that 
PYY increased POMC mRNA and induced electrophysiological 
activation of these neurons. It was suggested that the anorectic 
effects were due to activation of pre-synaptic inhibitory Y2 
receptors on arcuate NPY/AgRP neurons, resulting is a reduced 
inhibition of POMC neurons by the inhibitory neurotransmitter, 
γ-aminobutyric acid (GABA) (107). However, subsequent stud-
ies revealed that mice lacking functional POMC or MC4R were 
as susceptible as wild-type mice to the acute anorectic effects 
of peripheral PYY3–36 administration (110, 111). This indicates 
that although PYY3–36 may stimulate melanocortin production, 
melanocortin signaling is not necessary for its anorectic effects.
It has also been suggested that PYY3–36 acts to reduce food 
intake by signaling via peripheral neurons. The Y2R has been 
located on vagal afferent fibers, however, conflicting evidence 
has been found as to whether PYY3–36 requires an intact vagus 
to signal a reduction in food intake. Total subdiaphragmatic 
vagotomy did not attenuate the reduction in food intake com-
pared to sham operated mice, and instead was found to prolong 
the anorectic effects of PYY3–36. Hence, vagal tone may modulate 
the duration of action of intestinally secreted PYY3–36, but may not 
be required for short-term signaling (59). However, in a separate 
study, bilateral subdiaphragmatic vagotomy abolished both the 
anorectic effects of PYY3–36 and its ability to induce Fos expression 
in the ARC of rats following peripheral administration, indicating 
blockade of hypothalamic activation (112). Interestingly, a novel 
mechanism by which PYY-releasing cells may directly influence 
neuronal function has recently been proposed. PYY-expressing 
EECs were found to exhibit long cytoplasmic processes with 
some characteristics of neuronal processes, named neuropods, 
which directly contact enteric neurons (Figure  3). Culturing 
PYY-expressing EECs isolated by FACS with sensory neurons 
resulted in the development of neuropods, which contacted the 
neuronal neurites, from where a putative axon develops. These 
EEC–neuron connections suggest that L-cells may have the abil-
ity to directly participate in the transmission of sensory signals 
from the gut lumen (6, 7).
It has been proposed that PYY3–36 induces hypophagia by 
causing non-specific malaise. Conditioned taste aversion (CTA) 
protocols are commonly used as a paradigm for nausea in rodents, 
which lack the necessary anatomy for vomiting. Infusions of 
PYY3–36 have been dose-dependently associated with CTA in 
rats and mice, thought in part to be due to inhibition of gastric 
emptying (59, 113). A similar dose-dependent effect on nausea 
and abdominal discomfort has been found following exogenous 
administration of PYY3–36 in humans (49). The aversive effects of 
this peptide potentially limit its therapeutic use as an anti-obesity 
agent. However, interestingly, there is little connection between 
the nausea experienced and the level of food intake inhibition, 
suggesting that perhaps the nausea occurs at a threshold level, but 
is unconnected to the physiological satiating effects of PYY3–36 (13).
Nutrient-Sensing by L-Cells
Currently, the most effective treatment for obesity is bariatric 
surgery; the Roux-en Y-Gastric bypass is the most commonly 
performed procedure, and results in sustained weight loss, though 
the popularity of the vertical sleeve gastrectomy is increasing 
(114). In healthy individuals, the post-prandial response involves 
a complex cocktail of hormones, their release reflecting the 
ingested and absorbed macronutrients (115). The post-prandial 
GLP-1 and PYY response is reported to be blunted in obese 
patients (116). However, following bariatric surgery, patients 
exhibit increased post-prandial levels of anorectic gut hormones 
GLP-1 and PYY, and attenuated levels of ghrelin, an orexigenic 
hormone released from the stomach (117). In addition, ameliora-
tion of type 2 diabetes frequently occurs within days of surgery. 
It has been widely postulated that altered post-prandial gut hor-
mone levels may be responsible for at least some of the metabolic 
effects of bypass surgery. EECs are therefore a key area of interest 
in research into alternatives to bariatric surgery. Changes in 
intestinal morphology, in particular villus hyperplasia, have been 
implicated in the adaptive response following Roux-en Y-Gastric 
bypass and ileal interposition in rats (118, 119). A shift from 
absorptive to more secretory cell lineages, such as goblet cells, has 
also been observed (119, 120). In rats, villus proliferation occurs 
following the implantation of a duodenal–endoluminal sleeve, 
a device that acts as a physical barrier between nutrients and 
absorptive tissue (121). Increased villus length and surface area 
in these studies are associated with beneficial metabolic changes, 
including improved glucose homeostasis and increased post-
prandial GLP-1 secretion (122). Exploiting the mechanisms by 
which various dietary macronutrients activate GPCRs on L-cells, 
and hence, the release of endogenous GLP-1 and PYY represents 
a possible therapeutic target. It is thus important to understand 
the specific mechanisms by which L-cells sense different types of 
nutrients (23).
Receptors on the apical surface of open-type L-cells directly 
sense dietary components in the intestinal lumen, and respond to 
produce the appropriate endocrine response (Figure 1). The con-
tents of the intestinal lumen vary considerably with diet, requiring 
a number of specific receptors to detect the different macronutri-
ents that modulate the secretion of hormones. Secretion of GLP-1 
and PYY by L-cells is preceded by raised intracellular calcium 
and cyclic adenosine monophosphate (cAMP) levels. Calcium is 
released from intracellular stores following membrane depolari-
zation due to increased sodium-dependent cell excitability and 
calcium influx, leading to the exocytosis of hormone-containing 
vesicles. This signal is potentiated downstream by intracellular 
cAMP, which is increased by the action of Gs protein coupled 
receptors, further augmenting hormone release (20, 123). 
Recently, super-resolution microscopy has demonstrated that 
secretory vesicles from L-cells of the mouse, rat, pig, and human 
contain primarily either GLP-1 or PYY. This raises the possibility 
that either hormone may be selectively released from a micro-
domain of a single EEC (124). A specific combination of cellular 
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machinery may need to be activated in the L-cell to cause the 
differential release of GLP-1 or PYY. However, how these signals 
are integrated remains to be elucidated.
Protein-Sensing Receptors
Increasing dietary protein content by 10–15% promotes satiety, 
reduces overall calorie intake, and produces sustained weight loss 
in rodents and man, possibly due in part to the induced changes 
in circulating gut hormones (125–127). In both healthy and 
obese subjects, a high-protein meal increases plasma PYY levels 
significantly more than an isocaloric meal high in carbohydrate 
or fat, while PYY null mice are resistant to the satiating effects 
of protein (128). Chronic exposure to a high-protein diet also 
elevates post-prandial GLP-1 and increases satiety levels in 
healthy subjects (129).
The Peptone Receptor
It has been shown that peptones stimulate the release of CCK 
from I-cells, and stimulate GLP-1 release from ex vivo rat small 
intestine and colon, and from STC-1 cells. Activity of the pro-
glucagon gene promoter is also enhanced, leading to increased 
transcription (130). The peptone GPCR, GPR93, is highly 
expressed by cells of the duodenal mucosa, including L-cells. 
Activation of GPR93 by protein hydrolyzates, results in the 
transcription and release of CCK (24, 131). Peptide-transporter 
1 (PEPT1) is a brush-border transporter of di- and tri-peptides, 
located on L-cells of the small intestine and colon. Primary 
murine L-cell cultures have been shown to release GLP-1 in 
response to peptone administration, via PEPT1-dependent 
electrogenic uptake and activation of the CaSR (132). Hence, 
the larger fragments of protein hydrolysis may directly regulate 
proglucagon synthesis in the gut, and influence the secretion of 
its posttranslational products (130).
The Mu-Opioid Receptor
The oligopeptides produced by protein breakdown are also 
active at the mu-opioid receptor (MOR), an inhibitory GPCR. 
The MOR is present in the small intestine and brain, particu-
larly the nucleus accumbens. Agonism and antagonism of the 
central MOR has been shown to increase and decrease food 
intake, respectively (133, 134). Duraffourd et al. demonstrated 
that MORs located in the walls of the portal vein respond to 
the products of protein digestion in  vivo, to induce intestinal 
gluconeogenesis (135). This occurs as a result of a protein-
enriched diet, and leads to detection of increased portal glucose 
and signaling to the hypothalamic nuclei, which regulate food 
intake (136). These effects are abolished following denervation 
of the portal vein, providing a plausible link between the assimi-
lation of dietary protein in the gut, and the central induction of 
satiation (136).
The CaSR
The CaSR seems to promote the secretion of GLP-1 and PYY, 
and has thus been identified as a potential therapeutic target 
in the treatment of diabetes and obesity (23). The CaSR is 
proposed to act as an l-amino acid sensor in the gut, and has 
been identified on rodent and human L-cells (Figure  1). The 
CaSR is able to bind a wide range of amino acids. However, the 
most potent are the aromatic amino acids, l-phenylalanine and 
l-tryptophan (26). Mace et  al. reported that CaSR activation 
by the l-amino acids phenylalanine, tryptophan, asparagine, 
arginine, and glutamine, resulted in the secretion of the GLP-1 
and PYY. These responses were abolished in the presence of a 
CaSR inhibitor or the absence of extracellular calcium, identify-
ing amino acids as allosteric agonists that require the additional 
presence of calcium to initiate their effects (137). Voltage clamp-
ing of intact murine mucosa has shown that the response of 
the CaSR to l-glutamine is glucose sensitive. Peptone-triggered 
secretion of GLP-1 from murine primary colonic cultures is also 
abolished in the presence of CaSR antagonists and removal of 
extracellular calcium, though whether this effect represents the 
sensing of individual amino acids generated by initial protein 
breakdown, or the ability of small peptides to bind to the CaSR 
is unclear (132).
The GPRC6a
G-protein coupled receptor family C group 6 subtype A 
(GPRC6a) is closely related to the CaSR, though it preferentially 
binds the basic amino acids, l-arginine, l-lysine, and l-ornithine, 
whereas aromatic amino acids are inactive at this receptor (25). 
Similarly to the CaSR, GPRC6a possesses a calcium binding site 
on its extracellular domain, although with a weaker affinity than 
the aforementioned receptor, suggesting overlapping functions 
(138). GPRC6a is widely expressed throughout the body, includ-
ing the gut, liver, spleen, lung, heart, kidney, skeletal muscle, 
brain, and bone (138–140). Exon II of GPRC6a encodes part of 
an orthosteric binding site for endogenous ligands. Deletion of 
exon II in GPRC6a knockout mice triggers the development of a 
complex metabolic-like syndrome. This affects multiple organs, 
and results in consequences including demineralization of bone, 
hyperglycemia, and obesity, suggesting that GPRC6a plays a role 
in the coordination of nutrient sensing and metabolism in these 
tissues (141). However, an additional GPRC6a knockout, involv-
ing disruption of the 7-transmembrane and C-terminal region 
by deletion of exon VI, displays a normal bone phenotype and 
glucose tolerance (142). The expression of GPRC6a in the gut, 
and its activation by l-amino acids indicated that this receptor 
may mediate the effects of fluctuating dietary protein on energy 
homeostasis. The GPRC6a, closely related to the CaSR, has been 
cloned from human and rodent cells, and subsequently localized 
on the GLUTag L-cell line (139). Application of l-ornithine to a 
homologous model of the human GPRC6a leads to coupling of 
the receptor to Gq. The consequent activation of phospholipase C 
and increased intracellular calcium then stimulates the secretion 
of GLP-1 (25, 26). Pharmacological inhibition of the downstream 
pathway decreases the resulting GLP-1 exocytosis from GLUTag 
cells. Furthermore, following administration of l-ornithine and 
l-lysine, depletion of endogenous GPRC6a by a small interfer-
ing RNA attenuated the intracellular calcium response (143). 
However, studies using mice with the entire GPRC6a gene 
deleted, found that this receptor is not necessary for the effects of 
a high- or low-protein diet on body weight (144).
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The Taste Receptors
The capacity to sense the composition of food via taste allows for 
the selection of essential nutrients in the diet, in addition to the 
avoidance of harmful substances. Family C of the GPCRs also 
encompasses the type 1 taste receptors (T1Rs), formed of the 
subunits T1R1, T1R2, and T1R3. The combination of subunits 
T1R1 with T1R3 forms the umami taste receptor, a known 
l-amino acid receptor expressed in the lingual epithelium (26, 
145). The umami receptor is broadly responsive to aliphatic 
amino acids, but is particularly sensitive to l-glutamine and 
l-aspartate, the taste of which gives the umami receptor its name 
and enhances food palatability (146). The rodent and human 
T1Rs are only approximately 70% homologous, resulting in 
varying agonist affinities (147). The human T1R1 is consider-
ably more sensitive to glutamate than other amino acids, while 
the T1R2 is sensitive to artificial sweeteners, such as aspartame 
and cyclamate (148). Gustducin is a G-protein that plays a role 
in the downstream signaling transduction of taste from T1Rs. 
Coupling of the T1Rs to gustducin is thought to stimulate 
phosphodiesterase activity, leading to the hydrolysis of cAMP 
(149). Coexpression of T1R1/T1R3 with gustducin occurs in the 
fungiform and palatal taste buds and has also been reported in 
the GLP-1-producing STC1 cell line (150–152). However, it is 
currently unclear whether T1R1/T1R3 plays a physiological role 
in L-cell sensing of amino acids.
Specific Receptors
In addition to promiscuous amino acid receptors, specific amino 
acid sensors are expressed in the gut. Glutamate is the primary 
excitatory neurotransmitter in the central nervous system; 
however, its receptors are also widely expressed in the periphery, 
including the GI tract. Metabotropic glutamate receptors are 
GPCRs that are classified into three groups. Group III includes 
the metabotropic glutamate receptor 4, mGluR4, which is highly 
expressed in the distal gut, with highest expression in the proxi-
mal colon of mice and humans (153). Activation of mGluR4 by 
glutamate decreases intracellular cAMP production, through 
coupling to G proteins, which inhibit adenylyl cyclase activ-
ity (154). Glutamate is found in many food sources, including 
legumes and dairy products, and is converted to glutamine in the 
gut, liver, and kidneys (155, 156).
As a major product of protein digestion, glutamine is an impor-
tant fuel source for the gut that can enhance protein synthesis, 
particularly after injury (157). Glutamine acts as a GLP-1 secre-
tagogue in primary cell cultures and the GLUTag cell line, causing 
both initiation and further amplification of GLP-1 secretion, even 
at physiologically relevant levels (20, 123). The mechanism is 
unclear, though the initial step involves electrogenic uptake of 
the amino acid, followed by a downstream enhancing step, which 
in primary murine L-cells involves an increase in cytosolic Ca2+ 
and cAMP (20, 123). In further human studies, oral glutamine 
was found to be well tolerated, and to result in a biphasic increase 
of GLP-1 in the circulation of lean, obese, and diabetic subjects 
(27). Glutamine is commonly delivered as part of enteral and 
parenteral nutrition, due to its ability to preserve the integrity 
of the gut, which may be attributable to the co-release of GLP-2 
with GLP-1 (27, 158).
l-arginine is defined as a conditionally essential amino acid, 
as the bodies’ ability to synthesize it varies with age and injury 
status (159, 160). l-arginine is involved in the synthesis of nitric 
oxide, as well as that of several other amino acids, including 
l-glutamate, l-ornithine, proline, and creatine (161). A powerful 
secretagogue, it has long been known that l-arginine promotes 
the secretion of insulin and glucagon from the β- and α-cells of 
the pancreas, respectively, which may be partly due to its potent 
action at the GPRC6a receptor (162–164). Oral l-arginine stimu-
lates the secretion of GLP-1 and insulin in lean- and diet-induced 
obese mice in vivo. This effect was abolished in Glp1r knockout 
mice, and hence, the improvement of l-arginine-stimulated glu-
cose tolerance is dependent on this receptor (22). Furthermore, 
the addition of l-arginine to a low-protein diet was associated 
with a reduction in white adipose tissue and increased energy 
expenditure (165). Dietary supplementation of amino acids, 
such as glutamine and l-arginine, which potentiate the release 
of GLP-1 and PYY in vivo, may be useful as a nutritional therapy 
to enhance the response of the gut endocrine response in obese 
patients.
Mammalian Target of Rapamycin
Regulation of protein synthesis requires cells to sense nutrient 
availability. The mammalian target of rapamycin (mTOR) is 
a serine/threonine kinase that regulates cellular capacity for 
protein biosynthesis and cell growth by sensing intracellular 
amino acid levels. Autophagy involves the degradation of cellular 
protein into amino acids for use during conditions of starvation, 
a process inhibited by mTOR in an amino acid-rich environment. 
The levels of branched-chain amino acids, such as leucine, fall 
the most rapidly, with their depletion being the first to cause 
activation of mTOR (166). Dietary supplementation of branched-
chain amino acids following exercise has anabolic effects on 
human muscle, involving phosphorylation of mTOR (167). The 
anticancer drug rapamycin mimics the conditions of low-amino 
acid availability or limited nitrogen, restricting cell growth and 
inducing autophagy (168). l-glutamine is the preferred nitrogen 
source in cells, the balance of which provides the rate-limiting 
step for anabolic conditions (168). Uptake, and subsequent efflux, 
of l-glutamine is required for the activation of mTOR by essential 
amino acids, leading to tissue growth (21).
Adenosine Monophosphate-Activated  
Protein Kinase
Further regulation of protein metabolism occurs via adenosine 
monophosphate-activated protein kinase (AMPK), a sensor of 
adenosine nucleotides. Hydrolysis of adenosine triphosphate 
(ATP) increases the intracellular ratio of AMP to ATP, leading 
to the activation of AMPK (19). This negatively regulates down-
stream targets of TOR complex 1 (TORC1), and thus, responds 
to energy deficits by suppressing cell growth (169, 170). These 
signaling pathways converge further, through the regulation of 
Forkhead box class O (FoxO) transcription factors. Activation 
of AMPK and TORC1 leads to the phosphorylation of FoxO and 
the elevated expression of its transcription factors, respectively, 
with both processes acting to inhibit cell proliferation (171, 
172). Thus, AMPK acts as a nutritional sensor that influences 
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protein metabolism and may interact with protein-sensing 
mechanisms.
A thorough understanding of the ability of the cell surface 
and intracellular sensors, which detect the products of protein 
digest to regulate energy balance by responding to nutritional and 
hormonal signals may lead to new ways of exploiting the benefits 
of high-protein diets without requiring patients to adopt such 
regimes. Simultaneous pharmacological targeting of receptors 
enriched in the gut and pancreas, which have dual functions in 
the release of anorectic peptides from EECs and incretin effects, 
might be beneficial in diabetic obese patients.
Carbohydrate-Sensing Receptors
Most mammalian cells rely on a steady glucose supply as an 
energy source, though circulating levels must be kept low in order 
to avoid the toxic state of hyperglycemia (173). Carbohydrate 
sensing is directly related to glucose homeostasis, beginning with 
taste receptors in the mouth and subsequently glucose sensors 
in the gut. Activation of sweet taste receptors stimulates incretin 
hormone release from EECs and promotes glucose absorption 
via increased intestinal expression of the transporters, GLUT2 
and SGLT1 (119, 174). The tight, short-term control of glucose 
homeostasis allows sufficient flux of glucose to the brain, while 
avoiding states of hyperglycemia. However, there is no clear 
link between carbohydrate sensing and longer-term appetite 
regulation. An increase in blood glucose following either the 
consumption of carbohydrate in the form of breakfast cereal or 
intravenous infusion of glucose is not associated with decreased 
food intake, indicating that the glycemic response is not directly 
related to satiety (175, 176). Obese patients who have undergone 
Roux-en-Y gastric bypass are commonly reported to have 
resolution of the associated type 2 diabetes within days of the 
procedure. This precludes any weight loss, and may be partly due 
to the effects of duodenal isolation on acute intestinal glucose 
sensing and transport, resulting in the improved regulation of 
glycemia (119, 177).
Sodium-Glucose Transporter 1
Integrated glucose homeostasis relies on the ability of multiple 
tissue types to sense glucose levels. However, before glucose dis-
posal can occur, dietary carbohydrate must first be metabolized 
and absorbed from the gut lumen. Hydrolysis of carbohydrates 
by small intestinal brush-border enzymes produces monosac-
charides, such as glucose, that can then be absorbed. An essential 
component of this transepithelial transport system is the co-
transporter, SGLT-1, which uses the sodium electrochemical 
gradient produced by the Na+/K+ ATPase pump to allow glucose 
entry across the apical membrane and into enterocytes (178, 
179). Facilitated glucose transporters located on the basolateral 
membrane, such as GLUT2, subsequently allow passive diffusion 
of glucose into the interstitial space (180).
Enteroendocrine L-cells are directly glucose-responsive. 
Glucose-sensing leads to membrane depolarization and calcium 
entry through voltage-gated channels, leading to exocytosis of 
GLP-1-containing vesicles (27). Moriya et  al. determined that 
in  vivo injection of glucose into the upper intestine of mice 
increased circulating GLP-1 and GIP levels, and that this effect was 
prevented by coadministration of an SGLT-1 inhibitor. Injection 
of glucose into the colon did not affect incretin levels, consistent 
with localization of SGLT-1 mRNA in L-cells of the small intestine 
and very low detection in the colon (181). The non-metabolizable 
glucose analog and SGLT-1 agonist, α-methylglucopyranoside, is 
also a potent stimulator of GLP-1 release from primary intestinal 
L-cell cultures, highlighting this transporter as a major stimulator 
of hormone release from EECs (27).
ATP-Sensitive Potassium
The ATP-sensitive potassium (KATP) channel subunits, Kir6.2 
and Sur1, have been identified in primary L-cells expressed at 
levels similar to those seen in pancreatic cells, where they are 
known to be involved in insulin release (182). Tolbutamide, 
which blocks these channels, triggered GLP-1 release from 
primary L-cells, confirming the presence of functional KATP 
channels in L-cells. However, the exact function of these chan-
nels is unknown (27).
The Sweet Taste Receptor
Heterodimerization of subunits T1R2 and T1R3 of the above-
mentioned family C of the GPCRs, forms the sweet taste receptor. 
The sweet taste receptor is expressed on the lingual epithelium, 
but also acts as a carbohydrate sensor in the gut and STC1 cell line 
(151). Coupling of T1R2/T1R3 to the taste-associated G-protein, 
gustducin, mediates second messenger signaling cascades, and 
allows for the secretion of GLP-1 in the presence of glucose. 
This response is defective in gustducin-null mice, which have 
an impaired GLP-1 response to luminal glucose (152). Reimann 
et al. reported that although L-cells were unresponsive to arti-
ficial sweeteners at low concentrations, higher concentrations 
resulted in GLP-1 secretion in vitro, an effect that was additive 
with glucose, and may be due to activation of the sweet taste 
receptor (27). However, studies by Fujita et  al. indicated that 
oral administration of a range of sweeteners active at sweet taste 
receptors on the lingual epithelium, did not result in incretin 
secretion in vivo in the rat (183). The role of carbohydrate sensing 




The varying chain length and saturation of fatty acids and their 
derivatives confer distinct receptor affinities. The Gs-associated 
GPCR, GPR119, detects the endogenous saturated fatty-acid 
ethanolamides, such as oleoylethanolamide (OEA) (Figure  1). 
OEA is produced in the small intestine, and has a chain length of 
18 carbons, with one double bond. This high degree of saturation 
produces the greater efficacy of OEA at GPR119 than other etha-
nolamides (184). GPR119 is present on both pancreatic β-cells 
and intestinal L-cells. Activation in the pancreas mediates insulin 
secretion in the presence of glucose, via raised intracellular 
cAMP (185). Activation of GPR119 in the gut by the products of 
fat hydrolysis, leads to the release of GLP-1 and insulin secre-
tion in a glucose-dependent manner (186). Conversely, GPR119 
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agonists are able to stimulate GLP-1 secretion in the absence of 
nutrients in GLUTag cells (187). Daily intraperitoneal adminis-
tration of OEA to mice induces satiety and prevents weight gain, 
a feature that may be true of other GPR119 agonists (184, 188). 
Stimulation of GPR119 is coupled to increased proglucagon 
expression in GLUTag cells (189). This is further supported by 
the attenuated GLP-1 secretion in GPR119 knock-out mice in 
response to glucose. GPR119 may hence control GLP-1 synthesis, 
and pharmacological activation of this receptor may therefore 
enhance glycemic control and reduce food intake in diabetic 
patients (190).
SCFA Receptors
Short-chain fatty acids (SCFAs) comprise a chain of fewer 
than six carbons in length. They are produced by the bacterial 
fermentation of undigested carbohydrates, the main products 
being acetate, propionate, and butyrate (191). Putative receptors 
for SCFAs, include the free-fatty acid receptors (FFARs) 2 and 3, 
also known as GPR43 and 41, respectively. Both receptors couple 
to Gi/o, and activation thus leads to raised intracellular calcium 
and decreased cAMP. FFAR2 also exhibits dual coupling to Gq, 
an activator of phospholipase C (192). Localized in the human 
colon and ileum, FFAR2 and 3 are expressed by enteroendocrine 
L-cells that secrete PYY. However, FFAR3 is much more enriched 
in L-cells of the small intestine (29), while FFAR2 is expressed at 
higher levels in the human colon. Coexpression of FFAR2 and 
3 has not been observed in the same cells (191, 193). Recent 
evidence has suggested that increased intake of dietary fiber may 
reduce appetite by increasing the SCFAs produced by microbial 
fermentation in the colon, and thus, increasing the secretion of 
anorectic gut hormones (194). Propionate, in particular, may 
play an important role in satiety. Colonic infusion of SCFAs 
increases circulating PYY levels in  vivo in the rat, inhibiting 
upper GI tract motility consistent with the ileal brake (28). 
Acetate and propionate enhance GLP-1 secretion in murine pri-
mary cell cultures. Propionate stimulates the secretion of GLP-1 
and PYY from rodent colon in vivo and in vitro. This effect is 
significantly reduced in Ffar2-null mice, suggesting FFAR2 is 
important in SCFA-induced gut hormone secretion (30). The 
stimulatory effects of acetate on basal and glucose-stimulated 
GLP-1 release are also abolished in primary L-cell cultures from 
FFAR2 knock-out mice, though they were also found to be 
significantly reduced in FFAR3 knock-out tissue (29). Chronic 
delivery of propionate to the proximal colon of obese human 
subjects increases the production of PYY and GLP-1, reduces 
energy intake, and prevents weight gain. Targeted colonic pro-
pionate may therefore represent a novel and effective approach 
for weight management (195).
MCFA and LCFA Receptors
Medium chain fatty acids (MCFAs) and long-chain fatty acids 
(LCFAs) are agonists of the FFAR1 and 4, previously known as 
GPR40 and 120. An MCFA is formed of a 6–12 carbon chain, and 
LCFAs of a chain containing more than 12 carbons (196). FFAR1 
is expressed in the pancreatic β-cell, where evidence suggests 
it can influence glucose-stimulated insulin release (197). The 
effects of hyperlipidemia on glucose homeostasis may in part be 
mediated by this receptor (198, 199). FFAR1 is also expressed in 
GLP-1- and GIP-expressing cells of the GI tract, and the secretion 
of these hormones in response to oral fat is attenuated in Ffar1-
null mice. The activation of FFAR1 in EECs therefore provides a 
route for the indirect regulation of insulin secretion (32). FFAR4 
is expressed in the δ-cells of the pancreas, and widely in EECs. 
FFAR4 responds to unsaturated MCFAs and LCFAs by coupling 
to Gaq and increasing intracellular calcium, leading to GLP-1 
secretion (31, 33, 37). FFAR4-deficient mice gain more weight 
than wild-type controls, and show higher fasting plasma levels of 
glucose and insulin when fed a high-fat diet (200). Human obe-
sity has been associated with altered FFAR4 expression in adipose 
tissue, involving a deleterious Ffar4 mutation that is unable to 
transduce LCFA binding (200). While it feels counter intuitive 
to use lipids to treat obesity and metabolic disease, exploiting 
the pathways by which dietary lipid is sensed and drives satiety 
may be useful in the development of new pharmaceutical or 
nutraceutical agents.
Summary
Currently, the most effective treatment for obesity is bariatric 
surgery, specifically the Roux-en Y Gastric bypass. However, this 
method is not suitable for all, due the highly invasive nature and 
associated risks for patients, particularly those with cardiovascu-
lar problems. Due to the rapid degradation of endogenous PYY 
and GLP-1, and the difficulties in administration of peptide-based 
drugs, exploiting the mechanisms that lead to their continued 
release, such as the GLP-1 receptor agonist, Saxenda, might be 
a useful alternative approach to treating patients suffering from 
obesity and impaired glucose tolerance. Combination of phar-
macological treatments that act by targeting the nutrient-sensing 
receptors and transporters discussed above may ameliorate the 
defective satiety and glucose homeostasis pathways present 
in these patient groups. Likewise, the potential formulation of 
nutraceuticals, containing specific combinations of amino acids 
and other nutrient receptor ligands, may represent another 
approach (Table 1). The continued receptor deorphanization and 
elucidation of the cellular machinery by which the L-cell detects 
nutrients may thus prove valuable in the development of new 
treatments for diabetes and obesity.
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